{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:34:19Z","timestamp":1771547659102,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2004,5,1]]},"DOI":"10.1532\/ijh97.04005","type":"journal-article","created":{"date-parts":[[2007,10,18]],"date-time":"2007-10-18T13:52:32Z","timestamp":1192715552000},"page":"364-368","source":"Crossref","is-referenced-by-count":5,"title":["Progressive Myeloma after Thalidomide Therapy in a Patient with Immature Phenotype of Myeloma (Plasma) Cells"],"prefix":"10.1007","volume":"79","author":[{"given":"Yoshiko","family":"Okikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Takimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Noda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Imagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Okita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingo","family":"Fujimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","first-page":"484","author":"Alexanian, R","year":"1994","unstructured":"Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med. 1994;330:484-489.","journal-title":"N Engl J Med"},{"key":"E00002","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists Collaborative, Group","year":"1998","unstructured":"Myeloma Trialists Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.","journal-title":"J Clin Oncol"},{"key":"E00003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","author":"Atta, M","year":"1996","unstructured":"Atta M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.","journal-title":"N Engl J Med"},{"key":"E00004","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1200\/JCO.1994.12.4.759","author":"Cunningham, D","year":"1994","unstructured":"Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol. 1994;12:759-763.","journal-title":"J Clin Oncol"},{"key":"E00005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","author":"Barlogie, B","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood. 1999;93:55-65.","journal-title":"Blood"},{"key":"E00006","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","author":"Singhal, S","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341: 1565-1571.","journal-title":"N Engl J Med"},{"key":"E00007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0037-1963(00)90079-9","author":"Alexanian, R","year":"2000","unstructured":"Alexanian R, Weber D. Thalidomide for resistant and relapsing myeloma. Semin Hematol. 2000;37:22-25.","journal-title":"Semin Hematol"},{"key":"E00008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2002-09-2846","volume":"102","author":"Mileshkin, L","year":"2003","unstructured":"Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed\/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood. 2003;102:69-77.","journal-title":"Blood"},{"key":"E00009","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1349-7006.2002.tb02480.x","volume":"93","author":"Kakimoto, T","year":"2002","unstructured":"Kakimoto T, Hattori Y, Okamoto S, et al.Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res. 2002;93:1029-1036.","journal-title":"Jpn J Cancer Res."},{"key":"E00010","first-page":"3377","author":"Neben, K","year":"2002","unstructured":"Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res. 2002;8:3377-3382.","journal-title":"Clin Cancer Res"},{"key":"E00011","first-page":"688a","author":"Durie, BG","year":"2001","unstructured":"Durie BG, Stepan DE. Low-dose thalidomide alone and in combination: long-term follow up. Blood. 2001;98:688a.","journal-title":"Blood"},{"key":"E00012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/sonc.2002.34075","author":"Durie, BG","year":"2002","unstructured":"Durie BG. Low-dose thalidomide in myeloma: efficacy biological significance. Semin Oncol. 2002;29:34-38.","journal-title":"Semin Oncol"},{"key":"E00013","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1046\/j.1365-2141.2003.04345.x","author":"Anagnostopoulos, A","year":"2003","unstructured":"Anagnostopoulos A, Weber D, Rankin K, et al. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol. 2003;121:768-771.","journal-title":"Br J Haematol"},{"key":"E00014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2003.03.139","author":"Weber, D","year":"2003","unstructured":"Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol. 2003;21:16-19.","journal-title":"J Clin Oncol"},{"key":"E00015","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","volume":"15","author":"Rajkumar, SV","year":"2001","unstructured":"Rajkumar SV, Dispenzieri A, Fonseca R, et al.Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.","journal-title":"Leukemia."},{"key":"E00016","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V82.2.564.564","author":"Kawano, MM","year":"1993","unstructured":"Kawano MM, Huang N, Harada H, et al. Identification of immature and mature myeloma cells in the bone marrow of human myeloma. Blood. 1993;82:564-570.","journal-title":"Blood"},{"key":"E00017","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1182\/blood.V82.12.3721.3721","volume":"82","author":"Huang, N","year":"1993","unstructured":"Huang N, Kawano MM, Harada H, et al. Heterogeneous expression of a novel MPC-1 antigen on myeloma cells. Blood. 1993;82: 3721-3729.","journal-title":"Blood"},{"key":"E00018","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nrc952","author":"Hideshima, T","year":"2002","unstructured":"Hideshima T, Anderson KC. Molecular mechanism of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2: 927-937.","journal-title":"Nat Rev Cancer"},{"key":"E00019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0037-1963(01)90091-5","author":"Barlogie, B","year":"2001","unstructured":"Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol. 2001;38:21-27.","journal-title":"Semin Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.04005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T07:47:08Z","timestamp":1587973628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.04005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,5,1]]}},"alternative-id":["TA3H3776HPCJLER3"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.04005","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}